Stipple Bio came out of stealth Monday with $100 million and a thesis that’s essentially a bet against the entire cancer drug industry.
Founded by cancer biologists Aaron Ring and Jeff Landau, the company wants to do target identification differently. Instead of crowding around PD-1 and HER2, Stipple is hunting for more precise addresses on cancer cell surfaces — spots that are actually druggable and actually selective.
The ADC market is on fire, but the dirty secret is that Ring argues targeting misses drive most ADC failures: the antibody hits tumor cells, but it also hits healthy tissue expressing the same protein. Find a better epitope on the right protein and you fix the therapeutic window without redesigning the warhead.
That’s the platform play. Not an internal pipeline, but a targeting layer that every ADC developer in the industry needs. One licensing deal with a large pharma could justify the $100M raise alone.
Ring made his reputation mapping the proteins that sit on the outside of cells, the druggable surface of biology. If Stipple’s platform is an extension of that work, the science has a credible foundation.
No pipeline disclosed. No pharma partners announced. The $100M buys them time to generate the data that makes those conversations happen.
—Diana Kowalski